Trial Profile

An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; HTX 201 (Primary)
Indications Carcinoma; Urogenital cancer
Focus Adverse reactions; Proof of concept
Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development

Most Recent Events

13 Jan 2023 Status changed from active, no longer recruiting to discontinued.
18 Feb 2022 Planned End Date changed from 25 Feb 2022 to 28 Feb 2024.
18 Feb 2022 Planned primary completion date changed from 31 Dec 2021 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com